TAK1 selective inhibition: State of the art and future opportunities

Future Medicinal Chemistry

Volumn 7, Issue 1, 2015, Pages 23-33

  Kilty, Iain ^a   Jones, Lyn H ^a  

^a PFIZER INC   (United States)

Author keywords

covalent inhibitor; DFG out; inflammation; kinase; MAPK; NF B; TAK1

Indexed keywords

ENZYME INHIBITOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; DFG PEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OLIGOPEPTIDE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

BINDING ASSAY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; HUMAN; INFLAMMATION; NEOPLASM; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR DYNAMICS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

HUMANS; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR DYNAMICS SIMULATION; NF-KAPPA B; OLIGOPEPTIDES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84921417645     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.138     Document Type: Review

References (57)

1. Shibuya H, Yamaguchi K, Shirakabe K. et al. TAB1: an activator of the TAK1 MAPKKK in TGF-ß signal transduction. Science 272(5265), 1179-1182 (1996
2. De Nicola GF, Martin ED, Chaikuad A. et al. Mechanism and consequence of the autoactivation of p38a mitogenactivated protein kinase promoted by TAB1. Nat. Struct. Mol. Biol. 20(10), 1182-1190 (2013
3. Takaesu G, Kishida S, Hiyama A. et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell 5(4), 649-658 (2000
4. Broglie P, Matsumoto K, Akira S, Brautigan DL, Ninomiya- Tsuji J. Transforming growth factor ß-activated kinase 1 (TAK1) kinase adaptor, TAK1-binding protein 2, plays dual roles in TAK1 signaling by recruiting both an activator and an inhibitor of TAK1 kinase in tumor necrosis factor signaling pathway. J. Biol. Chem. 285(4), 2333-2339 (2010
5. Ishitani T, Takaesu G, Ninomiya-Tsuji J, Shibuya H, Gaynor RB, Matsumoto K. Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling. EMBO J. 22(23), 6277-6288 (2003
6. Shim J-H, Xiao C, Paschal AE. et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19(22), 2668-2681 (2005
7. Ajibade AA, Wang Q, Cui J. et al. TAK1 negatively regulates NF-?B and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils. Immunity 36(1), 43-54 (2012
8. Sato S, Sanjo H, Takeda K. et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 6, 1087-1095 (2005
9. Morioka S, Broglie P, Omori E. et al. TAK1 kinase switches cell fate from apoptosis to necrosis following TNF stimulation. J. Cell Biol. 204(4), 607-623 (2014
10. Arslan SÇ, Scheidereit C. The prevalence of TNFa-induced necrosis over apoptosis is determined by TAK1-RIP1 interplay. PLoS ONE 6(10), e26069 (2011
11. Dondelinger Y, Aguileta MA, Goossens V. et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ. 20(10), 1381-1392 (2013
12. Courties G, Seiffart V, Presumey J. et al. In vivo RNAimediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood 116(18), 3505-3516 (2010
13. Wang Y, Huang G, Vogel P, Neale G, Reizis B, Chi H. Transforming growth factor beta-activated kinase 1 (TAK1)-dependent checkpoint in the survival of dendritic cells promotes immune homeostasis and function. Proc. Natl Acad. Sci. USA 109(6), e343-e352 (2012
14. Sun L, Deng L, Ea C-K, Xia Z-P, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell 14(3), 289-301 (2004
15. Sato S, Sanjo H, Tsujimura T. et al. TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells. Int. Immunol. 18(10), 1405-1411 (2006
16. Schuman J, Chen Y, Podd A. et al. A critical role of TAK1 in B-cell receptor-mediated nuclear factor kB activation. Blood 113(19), 4566-4574 (2009
17. Shinohara H, Behar M, Inoue K. et al. Positive feedback within a kinase signaling complex functions as a switch mechanism for NF-kB activation. Science 344(6185), 760-764 (2014
18. Cheung PCF, Campbell DG, Nebreda AR, Cohen P. Feedback control of the protein kinase TAK1 by SAPK2a/p38a. EMBO J. 22(21), 5793-5805 (2003
19. Vink PM, Smout WM, Driessen-Engels LJ. et al. In vivo knockdown of TAK1 accelerates bone marrow proliferation/differentiation and induces systemic inflammation. PLoS ONE 8(3), e57348 (2013
20. Ninomiya-Tsuji J, Kajino T, Ono K. et al. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J. Biol. Chem. 278, 18485-18490 (2003
21. Choo M-K, Sakurai H, Koizumi K, Saiki I. TAK1-mediated stress signaling pathways are essential for TNF-a-promoted pulmonary metastasis of murine colon cancer cells. Int. J. Cancer 118(11), 2758-2764 (2006
22. Melisi D, Xia Q, Paradiso G. et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J. Natl Cancer Inst. 103(15), 1190-1204 (2011
23. Fan Y, Cheng J, Vasudevan S. et al. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy. Apoptosis 18(10), 1224-1234 (2013
24. Singh A, Sweeney MF, Yu M. et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148, 639-650 (2012
25. Ansell SM, Hodge LS, Secreto FJ et al. Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non- Hodgkin lymphoma. Blood Cancer J. 4, e183 (2014
26. Liu Q, Sabnis Y, Zhao Z. et al. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20, 146-159 (2013
27. Winssinger N, Barluenga S. Chemistry and biology of resorcylic acid lactones. Chem. Commun. 22-36 (2007
28. Schirmer A, Kennedy J, Murli S, Reid R, Santi DV. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc. Natl Acad. Sci. USA 103, 4234-4239 (2006
29. Kilty I, Green MP, Bell AS. et al. TAK1 inhibition in the DFG-out conformation. Chem. Biol. Drug Des. 82, 500-505 (2013
30. Jogireddy R, Dakas P-Y, Valot G, Barluenga S, Winssinger N. Synthesis of a resorcylic acid lactone (RAL) library using fluorous-mixture synthesis and profile of its selectivity against a panel of kinases. Chem. Eur. J. 15, 11498-11506 (2009
31. Wu J, Powell F, Larsen NA. et al. Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-oxozeaenol. ACS Chem. Biol. 8, 643-650 (2013
32. Ryckmans T, Edwards MP, Horne VA. et al. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis. Bioorg. Med. Chem. Lett. 19, 4406-4409 (2009
33. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Disc. 6, 881-890 (2007
34. Nishino M, Choy JW, Gushwa NN. et al. Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei. eLife 2, e00712 (2013
35. Ayers S, Graf TN, Adcock AF. et al. Resorcylic acid lactones with cytotoxic and NF-?B inhibitory activities and their structure-activity relationships. J. Nat. Prod. 74, 1126-1131 (2011
36. Bunnage ME, Chekler ELP, Jones LH. Target validation using chemical probes. Nat. Chem. Biol. 9, 195-199 (2013
37. Barglow KT, Cravatt BF. Activity-based protein profiling for the functional annotation of enzymes. Nat. Methods 4, 822-827 (2007
38. Cisar JS, Cravatt BF. Fully functionalized small-molecule probes for integrated phenotypic screening and target identification. J. Am. Chem. Soc. 134, 10385-10388 (2012
39. Moellering RE, Cravatt BF. How chemoproteomics can enable drug discovery and development. Chem. Biol. 19, 11-22 (2012
40. Barluenga S, Jogireddy R, Koripelly GK, Winssinger N. In vivo efficacy of natural product-inspired irreversible kinase inhibitors. Chembiochem 11, 1692-1699 (2010
41. Wei L, Wu J, Li G, Shi N. Cis-enone resorcylic acid lactones (RALs) as irreversible protein kinase inhibitors. Curr. Pharm. Des. 18, 1186-1198 (2012
42. Kamiyama H, Kakeya H, Usui T. et al. Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR. Oncol. Res. 17, 11-21 (2008
43. Kamiyama H, Usui T, Sakurai H. et al. Epoxyquinol B, a naturally occurring pentaketide dimer, inhibits NF-kB signaling by cross linking TAK1. Biosci. Biotechnol. Biochem. 72, 1894-1900 (2008
44. Saruwatari T, Praseuth AP, Sato M, Torikai K, Noguchi H, Watanabe K. A comprehensive overview on genomically directed assembly of aromatic polyketides and macrolide lactones using fungal megasynthases. J. Antibiot. 64, 9-17 (2011
45. Byth K, Palakurthi S, Yu L, Zhang Q: WO2008007072 A8 (2008
46. Lockman JW, Reeder MD, Robinson R. et al. Oxindole derivatives as inhibitors of TAK1 kinase. Bioorg. Med. Chem. Lett. 21, 1724-1727 (2011
47. Buglio D, Palakurthi S, Byth K et al. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood 120, 347-355 (2012
48. Hornberger KR, Berger DM, Crew AP. et al. Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1. Bioorg. Med. Chem. Lett. 23, 4517-4522 (2013
49. Hornberger KR, Chen X, Crew AP. et al. Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics. Bioorg. Med. Chem. Lett. 23, 4511-4516 (2013
50. Xi H, Lunney EA. The design, annotation, and application of a kinase-targeted library. Methods Mol. Biol. 685, 279-291 (2011
51. Millan DS, Bunnage ME, Burrows JL. et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J. Med. Chem. 54, 7797-7814 (2011
52. Lovering F, McDonald J, Whitlock GA. et al. Identification of type-II inhibitors using kinase structures. Chem. Biol. Drug Des. 80, 657-664 (2012
53. Johnson JM, Mason K, Moallemi C, Xi H, Somaroo S, Huang ES. Protein family annotation in a multiple alignment viewer. Bioinformatics 19(4), 544-545 (2003
54. Pauls E, Shpiro N, Peggie M. et al. Essential role for IKKß in production of type 1 interferons by plasmacytoid dendritic cells. J. Biol. Chem. 287, 19216-19228 (2012
55. Dzamko N, Inesta-Vaquera F, Zhang J. et al. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS ONE 7, e39132 (2012
56. Chooi KP, Galan SRG, Raj R. et al. Synthetic phosphorylation of p38a recapitulates protein kinase activity. J. Am. Chem. Soc. 136, 1698-1701 (2014
57. Xu Y, Zhou T, Espinosa-Artiles P, Tang Y, Zhan J, Molnár I. Insights into the biosynthesis of 12-membered resorcylic acid lactones from heterolygous production in saccharomyces cerevisiae. ACS Chem. Biol. 9, 1119-1127 (2014